Insulet : Corporate Presentation – May 2026

Published: 2026-05-06 07:34:52 ET PODD

Published on 05/06/2026 at 07:34 am EDT

Investor presentation

May 6, 2026

Chloe

Podder since 2021

The Pod has an IP28 rating for up to 25 feet for 60 minutes.

The PDM and Controller are not waterproof.

Non-GAAP Financial Measures

The Company uses the following non-GAAP financial measures:

Constant currency revenue growth, which represents the change in revenue between current and prior-year periods using the exchange rate in effect during the applicable prior-year period. Insulet presents constant currency revenue growth because management believes it provides meaningful information regarding the Company's results on a consistent and comparable basis. Management uses this non-GAAP financial measure, in addition to financial measures in accordance with generally accepted accounting principles in the United States (GAAP), to evaluate the Company's operating results. It is also one of the performance metrics that determines management incentive compensation.

Adjusted operating margin and adjusted earnings per share exclude the impact of certain significant transactions or events, such as legal settlements and medical device corrections, that affect the period-to-period comparability of our operating performance, as applicable.

Free cash flow, defined as net cash provided by operating activities less capital expenditures. Management uses this non-GAAP measure, in addition to GAAP financial measures, to evaluate our operating results.

Insulet presents the above non-GAAP financial measures because management uses them as supplemental measures in assessing the Company's performance, and the Company believes they are helpful to investors, and other interested parties as measures of comparative operating performance from period to period. They also are commonly used measures in determining business value and the Company uses them internally to report results.

These non-GAAP financial measures should be considered supplemental to, and not a substitute for, the Company's reported financial results prepared in accordance with GAAP. Furthermore, the Company's definition of these non-GAAP measures may differ from similarly titled measures used by others. Because non-GAAP financial measures exclude the effect of items that will increase or decrease the Company's reported results of operations, Insulet strongly encourages investors to review the Company's consolidated financial statements and publicly filed reports in their entirety. See appendix for a reconciliation of each non-GAAP financial measure to the most directly comparable GAAP financial measure.

Vision

A world where diabetes demands less every day, everywhere.

Mission

Born of empathy, driven by ingenuity, proven by science, we transform the lives of people with diabetes.

Verquise

Podder since 2025

The first AID system1 FDA-cleared for both type 1 and type 2 in the U.S.

#1 U.S. requested and prescribed AID system2,3

#1 U.S. new customer starts4 #1 EU new customer starts4

$2.7B

2025 revenue

600K+

Active customers5

Global markets

2020-25 CAGR

26%

Insulet

Other companies

66%

Insulet has driven two-thirds of market growth from 2020-25

50%

We are the clear leader in NCS7 share and approaching 50% share of global revenue today

Global AID market and Insulet Omnipod sales6, $B

+15%

~$5.7B

2020-25 CAGR

~$4.7B

~$2.9B

~$3.3B ~$3.5B

~$4.0B

$2.7

$2.0

$1.7

$0.8

$1.0

$1.2

2020 2021 2022 2023 2024 2025

Total revenue ($B) Adj. operating margin8 (%) Adj. EPS8 Free cash flow8 ($M)

$1.1

$1.3

$1.7

$2.1

$2.7

11.5%

9.5%

12.3%

14.9%

17.6%

$1.30

$0.86

$2.75

$3.24

$4.97

$70

$378

$305

2021 2022 2023 2024 2025

($4)

($180)

Revenue

+25% CAGR

Adj. Op. Margin Expansion

~610 bps

Adj. EPS

+55% CAGR

Free Cash Flow

+$558M

Our compelling investment thesis

Ample growth runway

in large, underpenetrated markets

Deep, durable, defensible moats

across technology, science, manufacturing, access, and brand

Robust innovation pipeline

to drive adoption and unlock new opportunities

Disciplined strategy

to develop markets, sustain top-tier growth, and enhance profitability

Strong financial position

and robust cash flow to fund growth

Today: $30B+

Total addressable market9 of ~8M PWDs

~$6B AID market today with line of sight to ~$9B by 2028

Total addressable market9, $B

$12B+

$9B+

~70%

$10B+

~65%

~55%

~40%

~25%

~5%

U.S. T1D

OUS T1D

Non-AID

CGM

U.S. T2D

basal-bolus

AID

Developing new markets

Leverage T1D OUS momentum to launch T2D OUS10

Broaden into U.S.

T2D basal-only

Expand into viable T1D

opportunity in Asia11

Total addressable market, # PWD lives

~3M

~2M

~17M

~4M

~8M

Current TAM

OUS T2D

sal-bolus10

U.S. T2D

basal-only

Asia T1D11

Long-term

TAM

Deep and wide competitive moats that capital alone cannot replicate

Efficient manufacturing & supply chain

$1B+

invested to build capabilities and drive sustainable cost advantage

Unique form factor

~$2B

investment in

R&D innovation

Broad access & affordability

100%

U.S. pay-as-you-go

pharmacy access

Brand loyalty

600K+

active customers, supporting brand and community engagement

A better way

2026 2027 2028

2028+

Omnipod 5 Ecosystem

Omnipod 6

Fully closed loop (T2D)

Future platforms

2026

Strengthening Omnipod 5 ecosystem

Algorithm improvements

Full CGM integration

Customer Benefits

Market Unlock

100 mg/dL target glucose

More time in auto mode and improved algorithm responsiveness

PWDs and prescribers seeking better glycemic control

Integrated with all major CGM sensors

All CGM users

Streamline office visits

Simplify onboarding

Use smart algorithms to identify trends into actionable insights

Enables HCPs to optimize care and empower Omnipod 5 users with their diabetes management

Customer Loyalty Deliver Improved Outcomes Strengthen Our Leadership Position

2027 2026

2027

Clinical study results & 510(k) filing

Better connectivity for a better wear experience

Launch

New app and controller for a better digital experience

Improved outcomes

Ease of use

Seamless connectivity

Over-the-air configurable Pod

Improved

algorithm

Omnipod 6 strengthens our leadership position while streamlining user experience

2026

Start pivotal study

2027

510(k) Filing

2028

Launch

Fully closed loop AID with no meal announcements Lower burden of managing T2D

Ready out-of-the-box: Designed for self-start

Designed for ease for HCPs to prescribe with no settings to start

Our U.S. business today:

The clear leader in AID

Established as the clear market leader

Investing to extend our lead - expanding beyond endocrinologists to activate prescribers and to fully unlock T1 and T2.

most requested and most prescribed AID system in U.S. 2,3

in new customer starts since 202312

Largest, most engaged patient community

Leading brand

U.S. Omnipod Revenue ($B)

$1.3

$1.5

$1.9

Most widely available access, at over

50K

pharmacies

30K+

active prescribers in U.S., and rapidly growing

>65%

of all new customer starts in the AID category

$0.9

$0.7

2021 2022 2023 2024 2025

+31% CAGR

Sustaining leadership in U.S. T1D

Our U.S. T1D strategy is designed to drive market penetration and grow our market share

~40%

Penetration Today

50-55%13

Penetration

By 2028

Achieved through

Leveraging demand generation for AID

To increase adoption and fuel market growth

Strengthening commercial excellence

To unlock new prescribers

Creating a superior user experience By delivering best-in-class service that simplifies the customer experience

Creating the U.S. T2D market

Our tailored U.S. T2D strategy is designed to more than double market penetration

~5%

Penetration Today

10-15%13

Penetration

By 2028

Achieved through

Positioning Omnipod as the standard of care Develop market by increasing awareness through both HCP and DTC channels

Creating differentiated T2D experience Reflecting the distinct T2D clinical context and optimizing the patient journey

Improving access

Demonstrating Omnipod's clinical and economic

value and removing barriers to adoption

Our international business today: Aspiration to lead in AID for

Leading AID market expansion

Growing durably and profitably in global markets

T1D and T2D

AID system for 'new-to-pump' users in Europe2

in new customer starts, since 202312

Accounts for

~30%

company revenues

International Revenue ($M)

$754

countries

Omnipod 5 available in

direct markets

$360 $363

$410

$523

International business spans

countries

Direct footprint since 201814

2021 2022 2023 2024 2025

+20% CAGR

Our international aspiration

Our international strategy is designed to drive T1D market penetration

~25%

Penetration Today

30-35%13

Penetration

By 2028

Achieved through

Building on our strength in Europe

With a focus on EU5, including entering Spain

Accelerating growth in other large geographies

Expanding access in Canada and Australia, and launching Omnipod 5 in the Middle East

Launch Omnipod 5 with access; invest commercially; broaden guidelines and coverage; and deliver continuous innovation

Disclaimer

Insulet Corporation published this content on May 06, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on May 06, 2026 at 11:29 UTC.